Table 4.

Meta-analysis of prognostic roles of mTOR/p-mTOR expression in patients with ESCC

Endpoint event	N	No. samples			Heterogeneity (I2, p)	Model	HR with 95 % CI	P value	Publication bias		Conclusion
		Total	PE	NE					Begg (p)	Egger (p)
Overall survival	6	713	381	332	I2 = 0.0 %, p = 0.493	Fixed	2.036 (1.582–2.620)	<0.001	1.0	0.663	Significant
Disease-free survival	3	330	197	133	I2 = 0.0 %, p = 0.970	Fixed	2.390 (1.637–3.490)	<0.001	1.0	0.941	Significant
Cancer-specific survival	2	308	145	163	I2 = 0.0 %, p = 0.853	Fixed	1.620 (1.179–2.229)	0.003	1.0	NI	Significant

CI confidence interval, ESCC esophageal squamous cell carcinoma, HR hazard ratio, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, NI no information, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin